Opus Genetics, Inc. (IRD)
About Opus Genetics, Inc.
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes seven adeno-associated virus (AAV)-based programs, led by OPGx-LCA5 for LCA5-related mutations and OPGx-BEST1 for BEST1-related retinal degeneration, with additional candidates targeting RHO, CNGB1, RDH12, NMNAT1, and MERTK. The company operates in one operating segment, which is the business of developing products related to vision performance and health.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $14.2M
- Net income
- -$49.6M
- Total assets
- $50.2M
- Market cap
- $328.0M
- Operating margin
- -271.9%
- Net margin
- -349.3%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $14.2M
- Operating expenses
- $52.8M
- Operating income
- -$38.6M
- Income tax
- $0
- Net income
- -$49.6M
- EPS (basic)
- $-0.80
- EPS (diluted)
- $-0.80
Balance sheet
- Total assets
- $50.2M
- Current assets
- $50.0M
- Total liabilities
- $34.9M
- Current liabilities
- $7.8M
- Shareholders’ equity
- $15.3M
Cash flow
- Operating cash flow
- -$35.3M
- Investing cash flow
- -$14.8M
- Financing cash flow
- $50.0M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $328.0M
- EPS (diluted)
- $-0.8
- Shares outstanding
- 106.5M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Nov 6, 2020
Opus Genetics, Inc. (IRD) Stock Price
- Reported a net loss of $49.6M in FY2025.
- Revenue grew 29% from FY2024 to FY2025.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Opus Genetics, Inc..
Write a review
News about Opus Genetics, Inc.
News & sentiment via Polygon.io
Opus Genetics, Inc.: frequently asked questions
Is Opus Genetics, Inc. an American company?
Opus Genetics, Inc. is a US-based company headquartered in Durham, North Carolina, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Opus Genetics, Inc. headquartered?
Opus Genetics, Inc. is headquartered in Durham, North Carolina, United States.
Is Opus Genetics, Inc. publicly traded?
Yes — Opus Genetics, Inc. is a publicly traded company. Its stock trades under the ticker symbol IRD on the NASDAQ.
What does Opus Genetics, Inc. do?
Opus Genetics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
